- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Hester Biosciences reported strong Q1 FY27 standalone performance: revenue up 14%, PAT soared 88%, and EBITDA grew 95%. Gross margins improved from 69% to 78% due to product mix and efficiency. Consolidated revenue declined 8% impacted by Nepal and Africa, but profitability got a boost from the Gates Foundation reducing Hester Africa's soft loan from USD 12 million to USD 5 million, waiving interest.
Poultry Healthcare shined with 48% growth, driven by institutional business and new health products. Animal Healthcare was affected by delays in government immunization programs, which management views as temporary. International operations, particularly Africa, are in a "formative period" amidst geopolitical challenges, but the company remains committed to long-term growth there. R&D continues with new regulatory dossier submissions. Overall capacity utilization is around 60-65%, including new BSL3 facilities. Management highlighted strong market response for their new low pathogenic avian influenza vaccine. The company maintains focus on strengthening its biological portfolio, market penetration, and operational excellence for sustainable long-term growth, despite short-term volatility from tender business. Consolidated debt stands at Rs. 103 crore.